Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Anti-HBV antiretrovirals may help ward off HBV infection in MSM

Three antiretrovirals that also help control hepatitis B virus (HBV) infection—tenofovir, emtricitabine, and lamivudine—may also prevent HBV infection, according to results of a retrospective analysis involving men who have sex with men (MSM) in the Netherlands.

Published
1 hour ago
From
International AIDS Society
Reducing the Risk for HIV, Hepatitis C Among Injection Drug Users

Coordinated education and counseling services can successfully control at-risk behaviors such as needle-sharing among injection drug users and thereby curb the spread of HIV and hepatitis C among this high-risk population, a new study has confirmed.

Published
1 hour ago
From
Infectious Disease Special Edition
Studies investigate presence of hepatitis C virus among gay and bisexual men

A review of epidemiological studies on hepatitis C in gay and bisexual men, including those who are HIV negative.

Published
2 hours ago
From
CATIE
Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence

A three-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C in a small

Published
23 hours ago
By
Keith Alcorn
AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. AbbVie plans to submit applications for regulatory approval of its regimen in the European Union in early May.

Published
23 April 2014
From
AbbVie press release
Gilead Beats Hepatitis C Sales Estimates by $1 Billion

Gilead Sciences Inc. (GILD) overwhelmed sales estimates for its new blockbuster hepatitis C pill in what analysts called the biggest drug start ever, raising questions about insurers’ ability to slow the use of the costly therapy.

Published
23 April 2014
From
Bloomberg
Sofosbuvir for hepatitis C works well despite multiple negative predictive factors

Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having four or more negative predictive factors, however,

Published
23 April 2014
By
Liz Highleyman
Sofosbuvir + new GS-5816 NS5A inhibitor is effective against hepatitis C genotypes 1-6

A new experimental NS5A inhibitor, GS-5816, was shown to be safe and effective when used in an interferon- and ribavirin-free dual regimen with sofosbuvir (Sovaldi) for people

Published
17 April 2014
By
Liz Highleyman
NHS England agrees funding for life-saving hepatitis C drug

NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C. Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sofosbuvir.

Published
17 April 2014
From
NHS England (press release)
England: Patients with end-stage liver disease caused by hepatitis C to get new drug

The NHS is to pay for around 500 people with end-stage liver disease caused by hepatitis C to receive Sofosbuvir, a new drug which could cure them, without waiting for guidance from the advisory body, Nice.

Published
17 April 2014
From
The Guardian
← First12345...133Next →

Filter by country